Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 388; číslo 23; s. 2159 - 2170
Hlavní autoři:	Eskander, Ramez N., Sill, Michael W., Beffa, Lindsey, Moore, Richard G., Hope, Joanie M., Musa, Fernanda B., Mannel, Robert, Shahin, Mark S., Cantuaria, Guilherme H., Girda, Eugenia, Mathews, Cara, Kavecansky, Juraj, Leath, Charles A., Gien, Lilian T., Hinchcliff, Emily M., Lele, Shashikant B., Landrum, Lisa M., Backes, Floor, O’Cearbhaill, Roisin E., Al Baghdadi, Tareq, Hill, Emily K., Thaker, Premal H., John, Veena S., Welch, Stephen, Fader, Amanda N., Powell, Matthew A., Aghajanian, Carol
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 08.06.2023
Témata:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer therapies Carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Cytotoxicity DNA Mismatch Repair Double-Blind Method Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Endometrium Female Gynecologic Oncology Gynecology Hematology Humans Hypotheses Immunotherapy Laboratories Mismatch repair Monoclonal antibodies Obstetrics Oncology Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Pembrolizumab Placebos Statistical analysis Survival Targeted cancer therapy Treatments in Oncology Tumors Japan
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!